What is a Model for End-Stage Liver Disease (MELD) score?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is a MELD Score?

The Model for End-Stage Liver Disease (MELD) score is an objective numerical scale ranging from 6 (less ill) to 40 (gravely ill) that predicts 3-month mortality risk in patients with end-stage liver disease using three laboratory values: serum bilirubin, serum creatinine, and international normalized ratio (INR). 1

Formula and Calculation

The MELD score is calculated using the following formula: MELD = 3.8 × log(bilirubin in mg/dL) + 11.2 × log(INR) + 9.6 × log(creatinine mg/dL) + 6.4 1

  • All three components are objective laboratory measurements, eliminating subjective clinical assessments 1
  • The score provides a continuous scale that directly correlates with estimated 3-month survival rates from 90% (score of 6) to 7% (score of 40) 1
  • Online calculators are available for ease of use 1

Original Development and Purpose

The MELD score was originally developed in 2001 to assess short-term prognosis in patients undergoing transjugular intrahepatic portosystemic shunts (TIPS) 1, 2

  • The model identified serum bilirubin, INR, and serum creatinine as the best predictors of 3-month postoperative survival 1
  • It has since been adopted by the United Network for Organ Sharing (UNOS) to stratify patients on liver transplantation waiting lists according to their risk of death within 3 months 1

Clinical Applications

Liver Transplantation Allocation

A MELD score ≥15 is the recommended threshold for listing patients for liver transplantation, as patients with MELD <15 may have lower 1-year survival with transplantation compared to without 1, 2

  • The MELD score is the primary basis for organ allocation in many countries, including the United States 1
  • Implementation in 2002 led to a sharp reduction in waiting list numbers and mortality without affecting post-transplant survival 3

Prognostic Thresholds

Different MELD cutoffs indicate varying levels of mortality risk:

  • MELD ≥18: Indicates poor prognosis in alcoholic hepatitis with significant short-term mortality risk 1
  • MELD >30: Patients face increased risk of mortality and morbidity after transplantation and require careful assessment 1
  • MELD >35: Associated with very high post-transplant mortality risk 1

Advantages Over Child-Pugh Score

The MELD score offers several advantages compared to the Child-Turcotte-Pugh (CTP) classification 1, 2:

  • Uses only objective laboratory tests rather than subjective clinical assessments of ascites and hepatic encephalopathy 1, 2
  • Includes renal function (serum creatinine), which is an established prognostic marker in liver disease 1, 2
  • Provides a continuous numerical scale rather than categorical classification 2
  • Eliminates bedside interpretation variability inherent in clinical assessments 1

The two overlapping parameters between MELD and CTP are serum bilirubin and prothrombin time/INR, while CTP additionally includes albumin, ascites, and encephalopathy 2

Limitations and Exceptions

Laboratory Variability

Interlaboratory variability in INR measurements has the largest impact on MELD scores, with mean differences of approximately 5 MELD points between laboratories 4, 5

  • Creatinine variability can account for differences up to 3 MELD points 5
  • Bilirubin measurements contribute minimally, accounting for only 1 point difference 5
  • Serum creatinine can be an unreliable marker of renal dysfunction in patients with cirrhosis 1

MELD Exceptions

Several conditions require "exception points" because their severity is not adequately captured by the MELD formula 1, 2:

  • Hepatocellular carcinoma (HCC): Receives additional points based on tumor size, number of nodules, AFP levels, waiting time, and response to downstaging 1
  • Hepatopulmonary syndrome 1
  • Portopulmonary hypertension 1
  • Primary hyperoxaluria 1
  • Amyloidosis 1
  • Recurrent cholangitis 6

Validation Limitations

The MELD score has not been validated as a predictor of survival in cirrhotic patients who are not on a liver transplantation waiting list 1, 2

  • It remains unclear whether MELD is superior to Child-Pugh score for predicting survival in non-transplant cirrhotic patients 1, 2
  • The MELD model favors patients with renal dysfunction, which may not always reflect liver disease severity 1

Modified MELD Scores

Several variations have been proposed to improve predictive accuracy 1, 2:

  • MELD-Na: Incorporates serum sodium levels 1, 2
  • Integrated MELD: Adds serum sodium and patient age 1
  • Delta MELD (DMELD): Measures change in MELD over time, which may be a better predictor of mortality 1, 2
  • MELD 3.0: The newest version includes patient sex and serum albumin with updated weights for other variables 7

Clinical Monitoring Recommendations

Serial calculation of MELD scores over time is justified for evaluating disease progression and adjusting transplant priority 1, 6

  • Regular monitoring helps track disease trajectory 6
  • Dynamic changes in MELD can provide additional prognostic information beyond a single measurement 1
  • Patients with MELD >20 should be considered for intensive care unit admission if organ failure or life-threatening complications develop 6

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

MELD and Child-Turcotte-Pugh Scoring Systems

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The International Normalized Ratio (INR) in the MELD score: problems and solutions.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2010

Research

Interlaboratory variability in assessment of the model of end-stage liver disease score.

Liver international : official journal of the International Association for the Study of the Liver, 2008

Guideline

Management Approach for Patients with High MELD Scores

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

MELD 3.0 in Advanced Chronic Liver Disease.

Annual review of medicine, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.